281 related articles for article (PubMed ID: 32125938)
21. Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.
Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Deapen D; Morrow M; Jagsi R; Katz SJ
JAMA Oncol; 2020 Apr; 6(4):e196400. PubMed ID: 32027353
[TBL] [Abstract][Full Text] [Related]
22. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
Yadav S; Hu C; Nathanson KL; Weitzel JN; Goldgar DE; Kraft P; Gnanaolivu RD; Na J; Huang H; Boddicker NJ; Larson N; Gao C; Yao S; Weinberg C; Vachon CM; Trentham-Dietz A; Taylor JA; Sandler DR; Patel A; Palmer JR; Olson JE; Neuhausen S; Martinez E; Lindstrom S; Lacey JV; Kurian AW; John EM; Haiman C; Bernstein L; Auer PW; Anton-Culver H; Ambrosone CB; Karam R; Chao E; Yussuf A; Pesaran T; Dolinsky JS; Hart SN; LaDuca H; Polley EC; Domchek SM; Couch FJ
J Clin Oncol; 2021 Dec; 39(35):3918-3926. PubMed ID: 34672684
[TBL] [Abstract][Full Text] [Related]
23. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
24. Frequency and spectrum of mutations across 94 cancer predisposition genes in African American women with invasive breast cancer.
Lovejoy LA; Rummel SK; Turner CE; Shriver CD; Ellsworth RE
Fam Cancer; 2021 Jul; 20(3):181-187. PubMed ID: 33083949
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
[TBL] [Abstract][Full Text] [Related]
26. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS
BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689
[TBL] [Abstract][Full Text] [Related]
27. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
28. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract][Full Text] [Related]
29. Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.
Rummel SK; Lovejoy L; Shriver CD; Ellsworth RE
Breast Cancer Res Treat; 2017 Aug; 164(3):593-601. PubMed ID: 28503720
[TBL] [Abstract][Full Text] [Related]
30. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465
[TBL] [Abstract][Full Text] [Related]
31. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
32. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
Apostolou P; Fostira F; Kouroussis C; Kalfakakou D; Delimitsou A; Agelaki S; Androulakis N; Christodoulou C; Kalbakis K; Kalykaki A; Sanidas E; Papadimitriou C; Vamvakas L; Georgoulias V; Mavroudis D; Yannoukakos D; Konstantopoulou I; Saloustros E
Int J Cancer; 2020 Sep; 147(5):1334-1342. PubMed ID: 32022259
[TBL] [Abstract][Full Text] [Related]
33. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
[TBL] [Abstract][Full Text] [Related]
34. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Alter BP; Best AF
Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
[TBL] [Abstract][Full Text] [Related]
35. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
[TBL] [Abstract][Full Text] [Related]
36. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
Sim WC; Lee CY; Richards R; Bettens K; Mottier V; Goh LL
Exp Mol Pathol; 2020 Oct; 116():104483. PubMed ID: 32531196
[TBL] [Abstract][Full Text] [Related]
37. Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
Apostolova C; Ferroum A; Alhassan B; Prakash I; Basik M; Boileau JF; Martel K; Meterissian S; Villareal Corpuz V; Wong N; Foulkes WD; Wong SM
Eur J Surg Oncol; 2024 Jun; 50(6):108324. PubMed ID: 38636249
[TBL] [Abstract][Full Text] [Related]
38. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.
Mittal A; Deo SVS; Gogia A; Batra A; Kumar A; Bhoriwal S; Deb KS; Dhamija E; Thulkar S; Ramprasad VL; Olopade O; Pramanik R
Ann Surg Oncol; 2022 Feb; 29(2):1423-1432. PubMed ID: 34601666
[TBL] [Abstract][Full Text] [Related]
39. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S
Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
